LCTX vs SPY
Lineage Cell Therapeutics Inc (LCTX) versus SPDR S&P 500 ETF Trust (SPY) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
SPDR S&P 500 ETF Trust (SPY) common stock listed on US.
Latest reported LCTX revenue for 2026-06-30 was $2.8M. Net income was -$3.3M. Revenue was up 62.0% from 2026-03-31 to 2026-06-30. LCTX currently screens at market cap $213.6M.
SPY does not have a complete income-statement cache yet.
LCTX currently screens at market cap $213.6M. SPY currently screens at market cap $0.
Not investment advice. Open the LCTX and SPY stock pages for the full models.
Not investment advice.